Skip to content
Subscriber Only

AstraZeneca Sees 60% of China Sales From New Drugs in Five Years

  • Drugmaker has eight new co-developed drugs in the pipeline
  • Novel therapies to make up bulk of China sales in five years
AstraZeneca Plc Medical Tablets As U.K. Pharma Company Rejects Pfizer's $98.7 Billion Bid
Photographer: Simon Dawson
Updated on

AstraZeneca Plc expects new and innovative treatments to contribute 60% of its China revenue by 2024, up from just a fraction now, as the country’s push to bring novel therapies faster to the market opens up opportunities for the global drugmakers.

Sales from newer drugs will likely overtake what the Cambridge, England-based drugmaker earns from off-patent medicines in the next five years, said Leon Wang, its executive vice president overseeing international markets, in an interview in the eastern Chinese city of Wuxi.